The urothelial carcinomas harbored three private mutations with specific annotation, two KRAS mutations (p.Gly13Asp and p.Ala146Thr) with resistance level R1, and the level 4 NF1 p.Arg2637Ter. The gene discussed is KRAS; the disease is urothelial carcinoma.